Relapse Refractory Multiple Myeloma: Real World Experience, Dr. Shaji Kumar, Mayo Clinic, USA

Shaji Kumar, MDПодробнее

Dr. Shaji Kumar - Mayo Clinic - Rochester, USAПодробнее

Dr. Kumar on Defining Multiple MyelomaПодробнее

New Frontline Combination in Multiple Myeloma, Dr. Shaji Kumar, Mayo clinic, USAПодробнее

HealthTree Podcast for Myeloma: Shaji Kumar, MD, Mayo Clinic on ETBs in MyelomaПодробнее

HealthTree Podcast for Multiple Myeloma: Dr. Shaji Kumar, Mayo ClinicПодробнее

New Treatment Regimens Used to Provide Maximum Benefit in Multiple MyelomaПодробнее

Phase I study of TNB-383B in R/R multiple myelomaПодробнее

Shaji Kumar, MD, provides perspective on the role of anti-CD38 antibodies changing multiple myelomaПодробнее

Lummicar-2: CT053 for R/R multiple myelomaПодробнее

Shaji Kumar on the Changing Immunotherapy Landscape in MyelomaПодробнее

Shaji Kumar, MD, shares the design and outcomes of the CARTITUDE-1 trial regarding multiple myelomaПодробнее

Updates in Multiple Myeloma - Dr. Shaji Kumar, Part 2Подробнее

New treatments for multiple myeloma - Mayo ClinicПодробнее

Dr. Kumar on Implications of BELLINI Trial in R/R Multiple MyelomaПодробнее

Analyzing the Outcomes With Different Treatment Techniques in MyelomaПодробнее

Shaji Kumar, MD, shares the take home message for physicians treating 1st line multiple myelomaПодробнее

CANOVA: venetoclax + dexamethasone for t(11;14) R/R myelomaПодробнее

Updates from the BELLINI trialПодробнее